TYMS and non-small cell lung carcinoma: Suppose that we want to investigate whether TS expression is a predictive marker for the clinical outcome of pemetrexed/cisplatin (PC) in patients with nonsquamous non–small-cell lung cancer (NSCLC) through a phase II trial.